Follow Spyre Therapeutics, Inc.. Every new filing, FDA action, and trial change, in your feed and a morning email, each linked to its source.
7 Stories in coverage 4 Programs 53 recruiting Registered trials 424B3 Nov 6 Latest SEC filing Nov 3 Latest story
Timeline 7 Pipeline 4 Trials 5
All7 Trials and readouts4 Filings and people3
Pipeline by stage
Phase 2 4
Details
Headquarters Waltham, MA Incorporated Delaware Industry Pharmaceutical Preparations Formerly Aeglea BioTherapeutics, Inc. (to 2023) Also known as Aeglea BioTherapeutics, Inc., SYRE How the company describes itself Spyre Therapeutics develops extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F for immunology indications, along with combination programs. The company is clinical-stage. source